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Abstract
Background: Tuberculosis (TB) is one of the major public health concerns worldwide. The detection of the
pathogen Mycobacterium tuberculosis complex (MTBC) as early as possible has a great impact on the effective
control of the spread of the disease. In our study, we evaluated the hyplex® TBC PCR test (BAG Health Care
GmbH), a novel assay using a nucleic acid amplification technique (NAAT) with reverse hybridisation and ELISA
read out for the rapid detection of M. tuberculosis directly in clinical samples.
Results: A total of 581 respiratory and non-respiratory specimens from our pneumological hospital and the
National TB Institute of Uzbekistan were used for the evaluation of the PCR assay. Of these, 292 were classified as
TB samples and 289 as non-TB samples based on the results of the TB cultures as reference method. The PCR
results were initially used to optimise the cut-off value of the hyplex® TBC test system by means of a ROC analysis.
The overall sensitivity of the assay was determined to be 83.1%. In smear-positive TB samples, the sensitivity of the
hyplex® TBC PCR test was estimated to 93.4% versus 45.1% in smear-negative samples. The specificity of the test
was 99.25%. Of the two specimens (0.75%) with false-positive PCR results, one yielded a culture positive for non-
tuberculous mycobacteria. Based on the assumption of a prevalence of 8% TB positives among the samples in our
diagnostic TB laboratory, the positive and negative predictive values were estimated to 90.4% and 98.5%,
respectively.
Conclusions: The hyplex® TBC PCR test is an accurate NAAT assay for a rapid and reliable detection of M.
tuberculosis in various respiratory and non-respiratory specimens. Compared to many other conventional NAAT
assays, the hyplex® TBC PCR test is in a low price segment which makes it an attractive option for developing and
emerging countries with high TB burdens.
Background
Worldwide, tuberculosis (TB) remains one of the lead-
ing infectious diseases, accounting for nearly 3 millions
deaths and over 8 million new cases annually [1]. The
vast majority of TB cases occur in developing or emer-
ging countries, particularly in Africa, South-East-Asia
and the countries of the former Soviet-Union. Among
them are up to 20% multidrug-resistant strains of Myco-
bacterium tuberculosis (MTB) [2]. In the control of the
spread of TB, accurate and early laboratory diagnosis
plays an important role.
Diagnosis of TB relies on the detection of acid-fast
bacilli (AFB) by microscopy (smear) and culture fol-
lowed by identification of isolates [3]. Microscopy is
rapid and inexpensive but has a low sensitivity (10
4 to
10
5 AFB per ml). Culture is slow but more sensitive,
detecting as few as 10
2 TB bacilli per ml. So far, culture
is considered the “gold standard” for laboratory confir-
mation of TB. The main disadvantage is its slowness
and therewith the delay in diagnostic of TB of up to
several weeks.
A major breakthrough in diagnosis of TB was there-
fore achieved by the introduction of nucleic acid ampli-
fication techniques (NAAT) to detect M. tuberculosis
complex (MTBC) directly in clinical specimens, which
can give results within one day. Compared to
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positive predictive values with smear-positive specimens
in settings in which non-tuberculous mycobacteria are
common, and (ii) in the possibility to rapidly confirm
the presence of MTB in 50 - 80% of smear-negative TB
c a s e s[ 4 , 5 ] .T h u s ,c o m p a r e dt oc u l t u r e ,N A A Tc a n
detect the presence of MTB weeks earlier for 80 - 90%
of patients suspected to have pulmonary TB. These
advantages can significantly improve patient care and
TB control efforts.
There are currently several commercial NAAT meth-
ods available of which each uses a different method to
amplify specific nucleic acid sequences of MTBC. These
include, for example, the Roche COBAS Amplicor MTB
test, the GenProbe Amplified M. tuberculosis Direct test
(AMTD), the BD ProbeTec-ET or the Hain GenoType
Mycobacteria Direct assay (GTMD). Available real-time
polymerase chain reactions (PCR) systems are, for exam-
ple, the Roche COBAS TaqMan MTB (CTM) test and
the Cepheid Xpert MTB test. A series of evaluation stu-
dies [6-16] have analysed and compared the accuracy of
commercial NAATs in both pulmonary and extrapul-
monary TB. They show that most of the NAATs have
high and consistent specificity and good positive predic-
tive values but modest and variable sensitivity, particu-
larly in smear-negative and extra-pulmonary TB.
An important issue is the implementation of NAATs
in developing countries with high TB burden. However,
prizes of commercial kits including required precision
instruments are not affordable for most of the countries
with high TB burden. Therefore, many of these coun-
tries use poorly validated in-house PCRs which show
more variability in their accuracy [17]. There is a high
demand for well validated, affordable commercial
NAATs for use in low-resource countries.
A novel commercial NAAT, which meets the demands
for a low cost system, has been recently introduced. The
hyplex® TBC test (BAG Health Care, Lich, Germany) is
a qualitative system for the detection of members of the
MTBC and is based on multiplex PCR followed by
reverse hybridisation to specific oligonucleotide probes
and ELISA detection.
In the present study we performed a clinical evalua-
tion of the hyplex® TBC test using well-characterised TB
and non-TB samples. PCR data were compared to the
results of conventional microscopy and culture techni-
ques. Finally, the potential impact of hyplex® TBC test
on laboratory diagnostics of TB was assessed.
Results
In the present study, we performed a comprehensive
clinical evaluation of the hyplex® TBC PCR in order to
estimate and optimise its diagnostic potential. A total of
581 clinical specimens from our frozen archive were
included comprising 292 TB samples and 289 non-TB
samples (Table 1).
Cut-off validation
The read-out end-point of the hyplex® TBC test is an
optical density (OD) value of the ELISA after reverse
hybridisation. In an initial step, we determined the best
cut-off value for the discrimination of TB and non-TB
specimens by means of a ROC (receiver operating char-
acteristic) curve analysis. Therefore, the sensitivity of the
test was determined for each potential cut-off value
between 0.100 and 0.800 and plotted against the rate of
f a l s ep o s i t i v er e s u l t s( F i g u r e1 ) .T h ec r i t e r i ao ft h eb e s t
cut-off were defined as (i) a false-positive rate as low as
possible ranging at least below 1% in order to minimise
the risk of the false diagnosis of a TB, and (ii) a sensitiv-
ity as high as possible. The optimal cut-value was set to
an OD of 0.400, where the false-positive rate was 0.75%
with sensitivity over 80% considering all specimens.
Table 1 Classification of samples
Clinical group Samples
(n)
TB POSITIVE 292
1. infection with M. tuberculosis, culture and smear positive 230
2. infection with M. tuberculosis, culture positive, smear
negative
62
TB NEGATIVE 289
3. no TB 269
4. no TB but culture positive for non-tuberculous
mycobacteria
20
TOTAL 581
Figure 1 ROC curve analysis. Based on the clinical classification of
specimens into TB or non-TB, hyplex® TBC results were analysed at
different cut-off values regarding the diagnostic performance.
Therefore, the rate of false-positive PCR results (100% minus
specificity) was plotted against the sensitivity at cut-off values of
0.100, 0.200, 0.300,0.325, 0.350, 0.375, 0.400, 0.500, 0.700 and 0.800,
corresponding to the optical densities of the ELISA read-out.
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T h ev e r s i o no ft h eh y p l e x ® TBC test used in this study
contained hybridisation modules for an internal control
(IC) allowing for the detection of inhibitors of the PCR
amplification. In general, samples with an ODIC <0 . 3 0 0
were considered as inhibited as long as the TBC PCR was
negative (ODTBC < 0.400). Twenty-four out of the 581
samples (4.1%) were excluded from further analysis due to
inhibition of the test reaction (Table 2). A higher rate of
inhibition was found in the non-TB group (7.6%) com-
pared to the TB group (0.7%). When looking at the differ-
ent types of specimens, the highest rate of inhibition was
found with urine samples (16.3%). Among samples of
respiratory origin, bronchial/tracheal secretes showed the
highest rate of inhibition (5.9%), followed by bronchoal-
veolar lavage (BAL) (4.0%) and sputum (2.4%) (Table 2).
Sensitivity
Of the remaining 557 samples without inhibitors, 290
were classified as TB samples based on the detection of
MTB in culture (Table 3). Of these, 228 (79%) were
smear-positive and 62 (21%) were smear-negative. 267
of 557 samples were considered as non-TB group based
on negative cultures for MTB. Among these, culture of
20 samples revealed non-tuberculous mycobacteria
(5 × M. intracellulare,5×M. gordonae,4×M. avium,
3×M. celatum, and 1 × each M. mucogenicum, M.
interjectum and M. kansasii). Overall, 243 of 557
(43.6%) yielded positive PCR results (OD ≥ 0.400; med-
i a nO Dv a l u e :1 . 3 2 ) ,a n d3 1 4n e g a t i v er e s u l t s
(OD < 0.400; median OD value: 0.147).
Of the 290 TB culture positive samples, 241 gave posi-
tive PCR results yielding an overall sensitivity of 83.1%
(Table 3). The sensitivity for smear-positive specimens
(n = 228) was 93.4%, for smear-negative specimens
(n = 62) 45.1%. Similar sensitivities were calculated
considering respiratory TB specimens only (n = 278):
the overall sensitivity was 84.2%; the sensitivities for
smear-positive and smear-negative samples were 93.7%
and 44.4%, respectively. Among non-respiratory samples,
all smear-positive TB samples (n = 4) and seven out of
eight smear-negative TB samples were detected by PCR
(sensitivities of 100% and 87.5%, respectively).
False negatives
Fifteen out of 228 culture and smear-positive TB samples
(6.6%) were negative by hyplex® TBC PCR (Table 3).
Repeat testing of these false-negative samples also yielded
negative results with hyplex® TBC. The existence of inhi-
b i t o r sc o u l db ee x c l u d e di nt h es a m p l e sb yh i g hO D IC
values ranging from 1.5 to 2.2. Only one sample showed
a somewhat lower ODIC which was however still above
the cut-off (ODIC = 0.37) indicating the presence of some
inhibiting factors which could have influenced the
TB-specific PCR. All false-negative samples (n = 15) were
re-assessed by the CTM PCR test, a real-time PCR sys-
tem based on MTBC specific sequences within the 16S
rRNA genes. Positive PCR results were obtained with all
specimens tested but one (data not shown). These data
indicate that a small proportion of TB positive samples
(smear and culture positive) were indeed not recognized
by the hyplex® TBC system.
Specificity
Of the 267 non-TB samples, 265 gave negative PCR
results yielding a specificity of 99.25%. A specificity of
99.5% was obtained for non-TB samples excluding cases
of infection with NTMs (n = 247). Considering NTM
samples only (n = 20), the specificity was 95%. Similar
values were obtained for respiratory non-TB samples (n
= 215) (Table 3). Among the non-respiratory samples,
all culture negative samples (n = 52) gave also negative
PCR results (100% specificity).
False positives
Seven out of the 267 MTB culture-negative specimens
were initially hyplex® TBC PCR positive and considered
as false-positives. Assessment of these samples by CTM
PCR gave negative results with all seven samples. Five of
these samples were also clearly negative on repeat with
the hyplex® TBC PCR, while in two samples, the positive
values of the first runs were confirmed on repeat. One
of these two specimens gave a positive culture for M.
intracellulare, the other one showed no mycobacterial
growth on culture. Together, based on merged PCR
data and culture results, two out of 267 MTB culture
negative specimens (0.75%) were finally classified as
false-positive hyplex® TBC PCR results (Table 3).
Table 2 Rate of inhibition
specimens (n) inhibited specimens (n) rate of
inhibition
(%)
ORIGIN OF
SAMPLE
Sputum 374 9 2.4
Bronchial
secrete
85 5 5.9
BAL 50 2 4.0
Urine 43 7 16.3
Punctuates/
fluids
28 1 3.6
Biopsies 1 0 0
CLINICAL GROUP
TB 292 2 0.7
non-TB 289 22 7.6
TOTAL 581 24 4.1
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Positive (PPV) and negative (NPV) predictive values lar-
gely depend on the prevalence of a disease. In particular,
with low prevalence, the specificity of a test has to be
very high, otherwise the PPV of the test will be poor.
The proportion of TB samples (52%) included in this
study was rather high and did not reflect the real situa-
tion of a TB diagnostic laboratory. In our laboratory,
real time PCR (CTM PCR) yields between 7.0% and
9.5% positive results, depending on year and season.
Assuming a mean rate of 8% of TB positive samples and
a number of approximately 3000 PCR assays per year,
the PPV of the hyplex® TBC test would be calculated to
90.4%, and the NPV to 98.5% (Table 4), based on the
sensitivity and specificity values found in this study
(83.1% and 99.25%).
Finally, the validity of the hyplex® TBC test was deter-
mined using an OD cut-off value for positive results of
0.200 as given in the instructions of the manufacturer.
Using this value, the sensitivity of the test would rise to
92% while the specificity would decrease to 85% (data
not shown). The PPV and NPV deduced from these sen-
sitivity and specificity estimates would be calculated to
34.8% and 99.1%, respectively (Table 4). Thus, the PPV
of the hyplex® TBC test is dramatically decreasing when
the cut-off is changed to OD 0.200, meaning that out of
1000 PCR-positive results only 348 truly indicate TB.
Furthermore, the rate of false positives of 15% at cut-off
of OD 0.200 would be above the acceptable limit.
Discussion
The hyplex® TBC PCR test is a new qualitative diagnos-
tic NAAT system for the detection of MTBC in human
Table 3 Sensitivity and specificity of the hyplex® TBC test
PCR results
positive (n) negative (n) total (n) sensitivity (%) specificity (%)
ALL SAMPLES 243 314 557
TB samples 241 49 290 83.1
smear-positive 213 15 228 93.4
smear-negative 28 34 62 45.1
non-TB samples 2 265 267 99.25
non-NTM 1 246 247 99.5
NTM 1 19 20 95.0
RESPIRATORY SAMPLES 237 257 494
TB samples 234 44 278 84.2
smear-positive 210 14 224 93.7
smear-negative 24 30 54 44.4
non-TB samples 2 213 215 99.1
non-NTM 1 195 196 99.5
NTM 1 18 19 94.7
NON RESPIRATORY SAMPLES 11 53 64
TB samples 11 1 12 91.6
smear-positive 4 0 4 100
smear-negative 7 1 8 87.5
non-TB samples 0 52 52 100
non-NTM 0 51 51 100
NTM 0 1 1 100
Table 4 Predictive values at cut-off values 0.400 and
0.200
cut-off 0.400 cut-off 0.200
PCR
pos
b
PCR
neg
b
TOTAL
a PCR
pos
b
PCR
neg
b
TOTAL
a
TB pos
(n)
199 41 240 221 19 240
TB neg
(n)
21 2739 2760 414 2346 2760
TOTAL (n) 220 2780 3000 635 2365 3000
PPV
c (%) 90.4 34.8
NPV
c (%) 98.5 99.1
a Based on the assumption of a mean rate of 8.0% true TB positive specimens
and a total number of 3000 specimens in a routine TB laboratory per year, the
resulting numbers of TB positive and negative samples were calculated.
b Based on the specificity and sensitivity values found in this study, the
numbers of expected PCR positive and negative results among 3000 were
calculated. Resulting numerical values were rounded.
c Positive and negative predictive values were deduced from calculated PCR
positive and negative results.
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cial NAAT tests, which range from about 20 to 35 Euro
(US$ 25 to 50) per test, it represents a low-cost system.
Costs of the hyplex® TBC test are estimated to ten to
twelve Euro per test in industrialised countries. For
developing countries, where most of the TB occurs, sig-
nificantly lower prices can be considered. In contrast to
real-time assays which require precision instruments as
well as capacity to maintain these instruments, the
hyplex® TBC test can be applied in all laboratories with
standard equipment for molecular biology techniques
and, therefore, allows for the application also in low-
budget laboratories, particularly in developing and emer-
ging countries. However, the low costs of equipment
and reagents go along with a significant increase in the
hands-on time. Whereas highly automated tests like
real-time assays may generate results within less than
two hours with very low hands-on time, the hyplex®
TBC test requires multiple workstations for specimen
preparation, target amplification and amplicon detection.
Including column-based DNA preparation, the assay will
take up to 6 hours to perform. This is comparable to
other NAAT assays which are largely performed manu-
ally like, for example, the GTMD assay [16]. Similar to
other NAAT assays, the hyplex® TBC test is certainly
suitable for partial automatation, for example by use of
full automated systems for hybridisation and ELISA
reading, which can significantly decrease the hands-on
time of the test.
Initially, the hyplex® TBC PCR test was validated by
the manufacturer using a set of 40 clinical specimens
(data not shown). In order to retrieve the highest sensi-
tivity possible, the cut-off value was set to 0.200 in the
manufacturer’s instructions. This cut-off was technically
controlled using DNA of different Mycobacterium and
non-mycobacterial species. None of 96 different strains
of different species other than Mycobacterium was posi-
tive (instruction for use, BAG Health Care). Out of 33
Mycobacterium strains, five MTBC strains (2 × MTB, 1
× M. africanum,1×M. cannettii,1×M. bovis)w e r e
positive. Twenty-eight NTM strains of 25 different spe-
cies were tested and three (2 × M. kansasii,1×M.
gadium) gave ELISA signals of about OD 0.300 that
were considered positive following the instructions of
the manufacturer. Thus, the “technical” sensitivity can
theoretically be assumed 100%, while the technical spe-
cificity would be only 97.6% given a cut-off value of OD
0.200. Using the same cut-off, the sensitivity in our
study set would be 92%, but the specificity would be as
low as 85%, meaning that every seventh positive PCR
result would be a false-positive one. However, the
improved sensitivity by use of cut-off value 0.200 does
not justify the risk of a false-positive diagnosis of TB in
15% of cases. Therefore, following our ROC analysis the
optimal cut-off value of the hyplex® TBC PCR assay was
set to an OD of 0.400 in our study. Using this corrected
value, the technical specificity determined by the manu-
facturer would indeed rise to 100%, while diagnostic
sensitivity and specificity still range within reasonable
limits.
The hyplex® TBC offers an overall sensitivity of 83.1%
and a specificity of 99.25%, when compared to culture
results as standard reference. The overall sensitivity of
83.1% was similar to that found for other NAAT assays
which tested respiratory and non-respiratory specimens
(range: 61.8% to 93.5%; median: 83.5%)
[7-10,12-16,18,19]. In contrast to some other studies
which found significantly reduced sensitivities for non-
respiratory specimens with various NAATs [7,10,14], the
hyplex® TBC assay even showed a higher sensitivity for
non-respiratory samples (91.6% for non-respiratory ver-
sus 84.2% for respiratory samples). Resolving against
smear-negative specimens, the sensitivity of the hyplex®
TBC test was rather in the lower range (45.1%) when
compared to other NAAT assays (range: 46% to 75,3%,
median: 56%) [8,9,11-13,15,18-20]. Resolving against
smear-positive specimens only, the sensitivity of the
hyplex® TBC test (93,4%) was in accordance with other
NAAT assays (range: 91,7% to 100%; median: 96,2%)
[8,11,13-15,18,19]. The overall specificity estimate of
99.25% for hyplex® TBC was remarkably high compared
to other NAAT assays (range: 97.4% to 100%; median:
99.2%) [7-9,11,14-16,18,20] and even ranged clearly
above the pooled specificity of 97% found by meta-ana-
lysis [6].
The positive and negative predictive values (90.4% and
98.5%) were calculated from specificity and sensitivity
estimates found in this study after extrapolation to a
total number of 3000 specimens per year and a preva-
lence of true TB positive specimens of 8%. When com-
pared to other evaluation studies which were based on
similar rates of true TB positive samples (range: 10% to
13.2%) [8,11,21], the PPV of 90.4% of the hyplex® TBC
was in the lower third (range: 88.5% to 100%) whereas
the NPV of 98.5% turned out excellent (range: 96.7% to
98.6%). In many studies, the prevalence of positive spe-
cimens in the respective setting of routine diagnostics
was not included in the calculation of the PPV and
NPV. This resulted mostly in an overestimation of the
significance of the values. Additionally, the values are
influenced by factors like the selection of specimens. For
these reasons, the comparison of PPV and NPV with
former studies and other assays is rather difficult.
Only two non-TB samples were finally classified as
false-positive. In one of them grew M. intracellulare.I t
is unlikely that the positive PCR resulted from a dual
infection of the patient with M. intracellulare and MTB.
Furthermore, the absence of MTB DNA in this
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some unspecific binding of the NTM amplification pro-
duct to TBC-specific probes could have caused this
false-positive result. False-positive PCR results due to
sporadic cross-reactivity with non-tuberculous mycobac-
teria has been suspected earlier also with other NAAT
systems [8,22,23]. As the technical validation of the
hyplex® TBC kit had indeed shown some unspecific
binding for single Mycobacterium species, it would be
possible also for the M. intracellulare. The second false-
positive specimen originat e df r o mac a s ew i t h o u ta
known MTB infection. It cannot be ruled out comple-
tely that very low amounts of MTB nucleic acids origi-
nating from an early TB infection may have led to
positive PCR results with hyplex® TBC.
Among smear-negative, culture-positive specimens, 34
out of 62 were not detected by hyplex® TBC. This was,
at least in part, due to the fact that the cut-off has been
increased from OD 0.200 to OD 0.400 in order to
reduce the false-positive rate to a minimum. It would
certainly be worth trying, whether the sensitivity could
be increased by applying higher volumes of sample. Our
evaluation was performed with a sample volume of 10
μl, but theoretically sample volumes up to 40 μl can be
applied. However, too much DNA may considerably
reduce the effectiveness of a PCR and, in return, would
lead to a higher rate of inhibition. The optimal volume
of specimen needs to be determined in further
investigations.
Seven percents of smear-positive, culture-positive sam-
ples also escaped the detection by hyplex® TBC. It is
unlikely that this was caused solely by too low amounts
of MTB DNA, since most of these specimens yielded
clearly positive smear microscopy results (at least
between 10 and 50 acid fast bacilli per 100 fields) and
re-assessment by CTM PCR gave positive results with
14 of 15 specimens. The hyplex® TBC PCR is based on
target sequences of a house keeping gene. It can be
speculated that missing of some of these TB samples by
hyplex® TBC was related to single nucleotide poly-
morphisms within this gene. This question should be
studied and the results may certainly help to optimise
the oligonucleotide probes used in the kit.
Conclusions
Hyplex® TBC is an accurate and reliable NAAT assay for
the direct detection of MTB in respiratory and non-
respiratory specimens. Similar to other commercial
NAATs, the hyplex® TBC assay is impacted by the com-
promise between specificity and sensitivity: specificity is
maximised at the cost of sensitivity. Compared to other
commercial NAAT systems, the hyplex® TBC assay shows
excellent specificity estimates but slightly lower sensitivity,
in particular for smear-negative TB specimens. Also, when
the assay is used as rapid confirmation test for smear-posi-
tive specimens one should be aware of the fact that a small
percentage of TB infections may be not detected. As it
holds true also for other NAAT assays, hyplex® TBC test
cannot replace culture but should be always carefully
interpreted along with clinical data and conventional tests.
Methods
Clinical specimens
A total of 581 clinical specimens, sent to our TB labora-
tory from April 2007 to October 2007, were taken from
our frozen archive. 514 specimens were sent to our
laboratory by German health centres for routine TB
diagnostics. Further 67 samples were sent by the
National DOTS centre of Uzbekistan to us as the supra-
national reference laboratory (SRLN) partner in the
frame of the national TB survey.
292 specimens were classified as TB samples based on
cultures being positive for MTB comprising 230 smear
positive and 62 smear negative specimens. 289 speci-
mens were classified as non-TB samples based on nega-
tive culture results. Among these, 20 samples were
positive for NTMs (Table 1). The whole study set
included 509 respiratory samples, 43 urine samples, 28
punctates and other fluid samples (pleural punctates,
abscess fluids, gastric secretions, etc) as well as one tis-
sue biopsy.
Processing of samples
All specimens were decontaminated according to DIN
58943-3:2008. In brief, specimens were 1:1 mixed with
N-acetyl-L-cysteine (NALC)-NaOH (final concentrations
1% NaOH, 0.7% NaCitrate, 0.25% N-acetyl-cysteine) and
rotated for 20 min. After neutralisation with 0.5 M
phosphate buffer (pH 6.8), and centrifugation (3000 × g
for 20 min) in order to concentrate the mycobacteria,
the sediment was resuspended in 1 ml phosphate buffer.
Smears were prepared from this suspension and stained
with auramin O following DIN 58943-32:2008. Fluores-
cence microscopy was performed with 400 × magnifica-
tion. Of the sediment, 100 μl each were transferred to
solid media (Loewenstein-Jensen, Stonebrink); 500 μl
were inoculated into Mycobacteria Growth Indicator
Tubes (MGIT™) (Becton-Dickenson, Heidelberg,
Germany) and incubated in the Bactec™ MGIT 960
incubator according to the manual of the manufacturer.
If demanded by the clinician, diagnostic PCR was per-
formed using the CTM PCR test (Roche Diagnostics
GmbH, Mannheim, Germany) following the instructions
of the manufacturer. The leftover suspension (400 to
700 μl) was frozen at-60°C until further processing in
the frame of the present study.
Media were incubated up to 8 weeks. In case a pri-
mary culture turned positive, the isolate was identified
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MTBC, Hain Lifesciences, Nehren, Germany).
Isolation of genomic DNA
DNA extraction was performed using the hyplex® Prep
module (BAG Health Care, Lich, Germany). In brief,
100 μl decontaminated, concentrated clinical sample
was added to 200 μl lysis buffer and incubated at 99°C
for 15 min. Following centrifugation, 200 μlo ft h e
supernatant was transferred to a new tube, mixed with
binding buffer and loaded onto a hyplex® Prep column.
Further steps including washing of columns and elution
in 100 μl elution buffer was done as recommended by
the manufacturer.
hyplex® TBC PCR
The hyplex® TBC test comprises the following work
steps: (i) multiplex PCR of internal control (IC)
sequences and genomic target sequences; (ii) heat-dena-
turation of amplification products; (iii) hybridisation to
specific probes immobilised onto microtiter strips; and
(iv) detection by ELISA followed by photometric mea-
surement at 450 nm. Different from the commercially
available version, the study version contained an internal
control for the detection of inhibitors of the amplifica-
tion of PCR products.
Amplification reaction
A5 0μl reaction volume contained 10 μlo fs a m p l e
lysate (or 10 μl negative/positive control included in the
kit), 1 μl nucleotide mix, 2 μlp r i m e rm i x ,5μl1 0×
PCR buffer, 0,4 μl Tth-DNA polymerase (5 U/μl) (BAG
Health Care, Lich, Germany), and 31,6 μlP C R - g r a d e
water. Thermal cycling was as follows: 5 min at 94°C,
then 45 cycles of 25 sec at 94°C, 25 sec at 52°C, 20 sec
plus 1 sec/cycle at 72°C, and final extension of 3 min at
72°C. After completing of the PCR, reaction mixtures
were used immediately for reverse hybridisation or
stored at 4°C until use within the next 16 hours latest.
Reverse hybridisation and detection
After heat-denaturation (10 min at 95°C) of the PCR
reaction mixture, 10 μl was immediately added to 100 μl
pre-cooled hybridisations o l u t i o ni nn e wt u b e sa n d
mixed thoroughly. 50 μl each was then quickly trans-
ferred by pipette to hybridisation cavities of the hyplex®
TBC and the hyplex® IC module. After incubation of the
microtiter plate for 30 min at 50°C, cavities were washed
three times with 200 μl pre-warmed (50°C) stringent
wash buffer followed by one washing step with normal
wash buffer. Freshly prepared conjugate solution
(100 μl) was added for 30 min at room temperature fol-
lowed by three washing steps at room temperature with
each 200 μl of washing buffer. 100 μlo fs u b s t r a t es o l u -
tion was then added to each well and after 15 min at
room temperature the reaction was stopped with 100 μl
stop solution. Measurement of the extinction of the
individual wells was done in a microtiter photometer at
450 nm with a reference wave length of 620 - 650 nm.
CTM PCR
Real-time PCR was performed on a COBAS® Taq-
Man®48 according to the manufacturer’si n s t r u c t i o n s
using the COBAS® TaqMan® MTB kit (Roche Diagnos-
tics, Mannheim, Germany) and 50 μl of DNA lysate. For
routine laboratory diagnostics, lysis of decontaminated,
concentrated specimens was performed using the
AMPLICOR® Respiratory Specimen Preparation Kit
(Roche Diagnostics, Mannheim, Germany) comprising
washing, lysis and neutralisation buffer. When using
DNA isolated by the hyplex® Prep Module as template,
the DNA had to be mixed with appropriate volumes of
lysis and neutralisation buffer prior to CTM PCR.
Validation and analysis of data
Diagnostic culture was considered as the “gold stan-
dard”. In those cases in which culture results were dis-
crepant from the PCR results, hyplex® TBC PCR was
repeated and samples were re-tested with the Roche
CTM test. Statistical data analyses were done using Epi
Info™ Version 3.5.1 accessible by CDC (Center for Dis-
ease Control and Prevention).
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